Autopsy report · NCT01151904

Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients

“Difficulty with patient recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months after it had already started.
• Ran for about 2 years 3 months before it stopped.
• 17 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Allergan

Sponsor type

Industry

Conditions

Glaucoma, Angle-Closure

Interventions

brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution; latanoprost

Participants

17

Sites

1

Countries

Thailand

Trials that died the same way

• Tibial Delayed Healing Pivotal Clinical Trial
  “Difficulty in patient recruitment” (98% match in meaning)
• Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)
  “Difficulties in patient recruitment” (98% match in meaning)
• Macular Edema Incidence/Severity Reduction With Nevanac
  “Patient recruitment difficulties” (97% match in meaning)
• Electrocochleography Along Cochlear Implant Auditory Rehabilitation
  “patient recruitment problem” (93% match in meaning)
• Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia
  “Patient recruitment insufficient” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.